SCHEDULE: Key Investors Boost Pacific Biosciences Stake to 6.8%

Madrone Capital Partners and related entities disclose increased beneficial ownership in Pacific Biosciences of California, Inc., reaching 6.8% of common stock.

Summary

• Madrone Capital Partners, LLC, Madrone Opportunity Fund, L.P., Jameson J. McJunkin, and Thomas Patterson each beneficially own 16,762,216 shares of Pacific Biosciences of California, Inc. common stock, representing 5.6% of the class.
• Shimoda Holdings, LLC beneficially owns 3,500,000 shares of common stock, representing 1.2% of the class.
• Gregory Boyd Penner beneficially owns an aggregate of 20,262,216 shares, representing 6.8% of the common stock, through shared voting and dispositive power over shares held by Madrone Opportunity Fund, L.P. and Shimoda Holdings, LLC.
• The ownership percentages are calculated based on 300,084,685 shares of common stock outstanding as of April 30, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed on May 12, 2025.
• The reporting persons explicitly disclaim status as a 'group' for the purposes of this Schedule 13G filing.

Sentiment

Score: 5

Explanation: This is a factual disclosure of beneficial ownership (Schedule 13G Amendment No. 4). It does not contain qualitative information about the company's performance, financial health, or operational outlook that would typically influence sentiment. The disclosure of a significant stake by institutional investors is generally neutral to slightly positive as it indicates continued investment, but without context of prior filings or company performance, it remains largely neutral.

Positives

• The disclosure of significant beneficial ownership by institutional and individual investors like Madrone Capital Partners and Gregory Boyd Penner may signal confidence in Pacific Biosciences of California, Inc.'s long-term prospects.

Negatives

• This filing, a Schedule 13G, is a disclosure of beneficial ownership and does not inherently contain negative operational or financial information about the company.

Risks

• The filing does not detail specific operational or financial risks related to Pacific Biosciences of California, Inc. It is a disclosure of beneficial ownership.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the company's future performance or strategic outlook.

Industry Context

This filing is a routine disclosure of significant beneficial ownership by investment entities and individuals in a publicly traded company. It does not provide broader industry trends or competitive analysis, but rather focuses on the ownership structure of Pacific Biosciences of California, Inc., a company operating in the biotechnology and genomics sector.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant ownership stakes held by key investors, which can influence perceptions of control and long-term investment interest.
• Management: Awareness of significant shareholders can influence strategic decisions and engagement with large investors.

Key Dates

Keywords

Pacific Biosciences, PACB, Beneficial Ownership, Schedule 13G, Madrone Capital Partners, Institutional Investor, Common Stock, SEC Filing, Biotechnology, Genomics